Growth of US Prescription Sales Slow in 2008 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Growth of US Prescription Sales Slow in 2008

ePT--the Electronic Newsletter of Pharmaceutical Technology

On Mar. 19, 2009, IMS, the leading provider of market research for the pharmaceutical and healthcare industries, reported that annual sales of prescriptions in the US grew 1.3% from $287.6 billion in 2007 to $291.5 billion in 2008. According to IMS, sales growth was slower in 2008 than in previous years.

IMS cited higher demand for generic drugs, a reduced number of new products, and low consumer demand because of the economic downturn as reasons for the slow growth.

Sales for approximately half of the top grossing pharmaceutical companies were down from 2007. The two top moneymakers, Pfizer (New York) and GlaxosmithKline (London), were millions of dollars down from their 2007 sales.  Companies that saw a rise in sales included Astrazeneca (London), Hoffman-LaRoche (Paris), Lilly (Indianapolis), and Teva Pharmaceutical Industries (Jerusalem).

Antipsychotic drugs were the most sold in overall sales through both retail and non-retail channels with lipid regulators, proton pump inhibitors, and seizure disorder medications following closely behind on the list of top selling drugs in 2008. Lipid regulators, antidepressants, ACE inhibitors, and beta-blockers were among the most widely dispensed prescriptions in 2008.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here